reports
Neurometrix Inc: 1 director
A director at Neurometrix Inc sold 20,000 shares at 13.560USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable T...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell® device usability by improving performance for users that maintain an active lifestyle. "We are pleased to have received this latest patent, which expands the Quell intellectual property portfolio. The ability to easily and intuitively interact with the Quell device is important to Quell users as daily use is co...
NeuroMetrix Closes $3.5 Million Equity Offering
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) today closed a $3.5 million private placement of 3,500 shares of Series F convertible preferred stock at a price of $1,000 per share that are convertible into 1,330,798 shares of common stock at a conversion price of $2.63 per share. The Company’s common stock closed on October 30, 2017 at $1.80 per share. Proceeds of the offering will be used for commercialization of Quell®, the Company's over-the-counter wearable device for relief of chronic pain and for general work...
NeuroMetrix Reports Q3 2017 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2017. The Company develops and markets novel therapies, based on neurostimulation and digital medicine, for chronic health conditions. The Company’s primary product is Quell®, which is an over-the-counter wearable neurostimulation device for treating chronic pain. The Company also has a diagnostic business based on its DPNCheck® product, which is a point-of-care test that pro...
NeuroMetrix, Inc. Announces Date for 2017 Third Quarter Financial Resu...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19, 2017 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 84863406. Internationally, the co...
NeuroMetrix Announces Participation at the 19th Annual Rodman & Rensha...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO) today announced it will be a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017, at Lotte New York Palace Hotel in New York City. Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investo...
Two Studies Derived from Quell Health Cloud to be Presented at Upcomin...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present two scientific posters at the upcoming PAINWeek national conference to be held in Las Vegas, NV, September 5-9. Both studies leveraged the Quell® Health Cloud, which connects with the Quell wearable pain relief device and its companion smartphone app. The cloud database stores the user's demographic and clinical profile, health metrics including pain, sleep, activity and gait, and device utilization. The Quell Health Cloud h...
NeuroMetrix Teams Up with U.S. Pain Foundation to Raise Awareness of C...
WALTHAM, Mass.--(BUSINESS WIRE)-- In recognition of Pain Awareness Month this September, NeuroMetrix, Inc. (Nasdaq: NURO) is partnering with the U.S. Pain Foundation, a nonprofit organization dedicated to serving those who live with pain conditions and their providers, to raise awareness of the issues impacting the chronic pain community. During September, NeuroMetrix will donate a portion of sales of the company’s Quell® Wearable Pain Relief Technology™ to the U.S. Pain Foundation. Through this partnership, NeuroMetrix will ...
NeuroMetrix Announces Issuance of New U.S. Patent for Automated Contro...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,731,126. The patent covers novel technology whereby the Quell® device automatically modulates therapeutic neurostimulation based on the user’s sleep characteristics. In addition, the patent includes claims related to providing device users with feedback about their sleep. Most people with chronic pain experience sleep disorders, most often insomnia. Inadequate sleep worsens ...
NeuroMetrix Announces DPNCheck Distribution Agreement with Fukuda Dens...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported an agreement with Fukuda Denshi for DPNCheck® distribution in Japan. DPNCheck is NeuroMetrix’ rapid, accurate, and quantitative point-of-care test to detect diabetic peripheral neuropathy. Diabetes is a serious health issue in Japan with a prevalence of 5.7% of the adult population or over 7 million people. DPNCheck received regulatory clearance and was commercially launched in Japan during 2014. Distribution was handled by Omron Healthcare until the sal...
NeuroMetrix Announces Shipment of 100,000th Quell Device Since Launch ...
BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported today that it had shipped its 100,000th Quell® wearable device for treatment of chronic pain since commercial launch in mid-2015. Quell device shipments have posted growth in each of the eight sequential quarters that it has been on the market. Quell has been recognized by numerous awards over the past two years including the SXSW Innovation Award, SBANE Innovation Award, APMA Seal of Approval, and as a finalist for the Best of CES. It has advanced from its commercial...
NeuroMetrix Reports Q2 2017 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended June 30, 2017. The Company develops and markets novel therapies, based on neurostimulation and digital medicine, for chronic health conditions. The Company’s primary product is Quell®, which is an over-the-counter wearable neurostimulation device for treating chronic pain. The Company also has a diagnostic business based on its DPNCheck® product, which is a point-of-care test that provides...
NeuroMetrix, Inc. Announces Date for 2017 Second Quarter Financial Res...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 second quarter financial results before the opening of the market on Thursday July 20, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on July 20, 2017 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 30255790. Internationally, the confere...
NeuroMetrix Announces $7.0 Million Private Placement of Preferred Stoc...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it has entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 7,000 shares of Series F convertible preferred stock at a price of $1,000 per share. The Company expects to receive gross proceeds from the offering of $7.0 million, in an initial tranche of $3.5 million and a second tranche, which is subject to shareholder approval and an effective resale regis...
NeuroMetrix Reports Promotion of Michael MacDonald to Senior Vice Pres...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that Michael MacDonald has been promoted to SVP and General Manager of Diagnostics. In this role, Mr. MacDonald will oversee the Company’s diagnostic products which include DPNCheck® and ADVANCE™. Mr. MacDonald has been with NeuroMetrix for over 15 years, most recently as SVP of Commercial Operations. In this role, he has been responsible for the DPNCheck business in the Americas, Europe, Middle East and India. Prior roles included Vice Presiden...
NeuroMetrix Provides Update on Quell Health Cloud Including Promotion ...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its data science initiative and the related Quell® Health Cloud. Data science consists of the development of large cloud databases and the use of powerful analytical tools such as machine learning and artificial intelligence. The Quell device and its companion smartphone app connect seamlessly with the Quell Health Cloud. The cloud database stores the user’s demographic and clinical profile, health metrics including pain, sleep, act...
NeuroMetrix Provides Update on Quell Wearable Pain Relief Clinical Pro...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell® clinical program. Quell is a wearable non-invasive neurostimulator that provides widespread analgesia for chronic pain. In addition to delivery of therapy, the device and its associated smartphone app track utilization and health metrics including pain, sleep, activity and gait. The objective of the clinical program is to build clinical credibility for Quell technology, further scientific understanding of its mechanism of...
NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable P...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,675,801. The patent covers novel mechanisms to help Quell® users safely obtain pain relief therapy over prolonged time periods. More specifically, the patent includes claims for technology to monitor the amount of time that Quell is worn both continually and in the aggregate, and to provide notifications to the user to maximize safety. "We are pleased to have receiv...
NeuroMetrix to Present at the Marcum Microcap Conference on June 16, 2...
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the upcoming 2017 Marcum Microcap Conference at the Grand Hyatt Hotel in New York City. Dr. Gozani intends to provide an update on the Company's business activities including the Quell® Wearable Pain Relief Technology™. The NeuroMetrix presentation is scheduled for Friday, June 16, 2017, at 10:00 a.m. EST. A live audio webcast will be available on the ...
NeuroMetrix Exhibits Quell Wearable Technology at 31st Annual SLEEP Me...
BOSTON--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) is showing Quell®, its 100% drug-free Wearable Pain Relief Technology™ to sleep medicine professionals from around the world at SLEEP 2017, the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) June 5-7, 2017 in Boston, MA. SLEEP 2017 is the largest scientific meeting dedicated exclusively to sleep medicine and sleep research. Experts recommend that adults get between seven and nine hours of sleep each night to function at the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.